The Relationship between Smoking History with ECOG Score, EGFR Mutation Status, and Clinicopathology Data of NSCLC Patients: Preliminary Study
DOI:
https://doi.org/10.36497/jri.v46i1.1044Keywords:
ECOG, EGFR mutation, non-small cell lung carcinoma, smoking historyAbstract
Background: Patients with non-small cell lung cancer (NSCLC) have a poor outcome. Mutations in the EGFR gene play a crucial role in determining treatment options and prognosis. Smoking history, clinicopathological features, including patient performance, and EGFR gene mutation have served as clinical guidelines for monitoring. This study aims to examine the association between smoking history and ECOG score, EGFR mutation status, and clinicopathological characteristics of patients with NSCLC in Yogyakarta.
Methods: An observational and analytic study, with a retrospective cohort design from 32 patients diagnosed with NSCLC. Data on smoking history, clinicopathological characteristics, ECOG performance scores, and EGFR mutation types (Exon 19 deletion and Exon 21 L858R) were extracted and concluded from medical records. The relationship between these variables was analysed using the Chi-square test.
Results: The analysis began by exploring the relationship between smoking history and initial ECOG performance scores. It was discovered that non-smokers exhibited poorer initial ECOG scores (P=0.025). Smoking history was significantly associated with specific EGFR mutation types (P=0.009), but not with overall EGFR mutation status. The analysis revealed that deletions on Exon 19 were mainly found in patients who smoked, whereas mutations in Exon 21 were uniquely present in non-smokers. Clinical follow-up also shows an association (P=0.002). This finding suggests that smoking behaviour interferes with the carcinogenesis of NSCLC.
Conclusion: The relationship between smoking history, performance status, exon-specific EGFR mutations, and clinical follow-up suggests differences in the carcinogenic mechanisms of NSCLC exon-specific mutations, highlighting biological diversity and emphasizing the need for detailed molecular studies to improve prognostic accuracy.
Downloads
References
1. Abbasian MH, Ardekani AM, Sobhani N, Roudi R. The role of genomics and proteomics in lung cancer early detection and treatment. Cancers (Basel). 2022;14(20).
2. Huang L, Liu Y, Yi C, Han L, Li S, Li X, et al. Pathological findings of pulmonary papillary adenoma with EGFR mutation and literature review: Two cases report. J Cardiothorac Surg. 2024;19:336.
3. Zheng H, Zhang Y, Zhan Y, Liu S, Lu J, Feng J, et al. Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma. Cancer Manag Res. 2019;11:6139–50.
4. Syahruddin E, Soeroso NN, Ananda FR, Wulandari L, Setijadi AR, Ermayanti S, et al. The time to progression in lung adenocarcinoma patients receiving first- and second-generation EGFR-TKI in Indonesia. Jurnal Respirasi. 2025;11(1):22–30.
5. Tseng CH, Chiang CJ, Tseng J Sen, Yang TY, Hsu KH, Chen KC, et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017;8(58):98384–93.
6. Datta SS, Ghosal N, Daruvala R, Chakraborty S, Shrimali RK, Van Zanten C, et al. How do clinicians rate patient’s performance status using the ECOG performance scale? A mixed-methods exploration of variability in decision-making in oncology. Ecancermedicalscience. 2019;13:913.
7. Chang CY, Chen CY, Chang SC, Lai YC, Wei YF. Efficacy and prognosis of first-line egfr-tyrosine kinase inhibitor treatment in older adults including poor performance status patients with egfr-mutated non-small-cell lung cancer. Cancer Manag Res. 2021;13:7187–201.
8. Sekihara K, Kawase A, Matsubayashi Y, Tajiri T, Shibata M, Hayakawa T, et al. Impact of smoking on resected lung cancer depends on epidermal growth factor receptor mutation. Interdisciplinary Cardiovascular and Thoracic Surgery. 2024;39(1):ivae109.
9. Ying X, Freedland KE, Powell LH, Stuart EA, Ehrhardt S, Mayo-Wilson E. Determining sample size for pilot trials: A tutorial. BMJ. 2025;390:e083405.
10. Aye PS, McKeage MJ, Tin Tin S, Khwaounjoo P, Elwood JM. Factors associated with overall survival in a population-based cohort of non- squamous NSCLC patients from northern New Zealand: A comparative analysis by EGFR mutation status. Cancer Epidemiol. 2020;69:101847.
11. Shen CH, Yang LY. The association between postdiagnosis smoking cessation and survival in advanced non-small cell lung cancer patients in Southern Taiwan: A retrospective cohort study. Tzu Chi Med J. 2025;37(2):211–5.
12. Jiang H, Zhu M, Li Y, Li Q. Association between egfr exon 19 or exon 21 mutations and survival rates after first-line egfr tki treatment in patients with non-small cell lung cancer. Mol Clin Oncol. 2019;11(3):301–8.
13. Nagl L, Pall G, Wolf D, Pircher A, Horvath L. Molecular profiling in lung cancer. Memo - Magazine of European Medical Oncology. 2022;15:201–5.
14. Marino FZ, Bianco R, Accardo M, Ronchi A, Cozzolino I, Morgillo F, et al. Molecular heterogeneity in lung cancer: From mechanisms of origin to clinical implications. Int J Med Sci. 2019;16(7):981–9.
15. Passaro A, Malapelle U, Del Re M, Attili I, Russo A, Guerini-Rocco E, et al. Understanding EGFR heterogeneity in lung cancer. ESMO Open. 2020;5(5):e000919.
16. Testa U, Castelli G, Pelosi E. Lung cancers: Molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers (Basel). 2018;10(8):248.
17. Zhang Y, Kang S, Fang W, Hong S, Liang W, Yan Y, et al. Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: A meta-analysis. Clin Lung Cancer. 2015;16(2):144–51.
18. Popat S, Liu S V., Scheuer N, Gupta A, Hsu GG, Ramagopalan S V., et al. Association between smoking history and overall survival in patients receiving pembrolizumab for first-line treatment of advanced non-small cell lung cancer. JAMA Netw Open. 2022;5(5):e2214046.
19. Wang X, Ricciuti B, Alessi J V., Nguyen T, Awad MM, Lin X, et al. Smoking history as a potential predictor of immune checkpoint inhibitor efficacy in metastatic non-small cell lung cancer. J Natl Cancer Inst. 2021;113(12):1761–9.
20. Wicaksono A, Adisasmita AC, Putra AC. The impact of smoking degree on one year survival of non-small cell lung cancer (NSCLC) at Persahabatan Hospital. Jurnal Epidemiologi Kesehatan Indonesia. 2024;8(2):129–34.
21. Jiang DD, Wang ZX, Li HY, Liu JM, Cui ML, Luo YX. Experiences of patient delay among lung cancer patients in South China. BMC Cancer. 2024;24(1):1527.
22. Asmara OD, Tenda ED, Singh G, Pitoyo CW, Rumende CM, Rajabto W, et al. Lung cancer in Indonesia. Journal of Thoracic Oncology. 2023;18(9):1134–45.
23. Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist. 2012;17(7):978–85.
24. Dawe DE, Rittberg R, Syed I, Shanahan MK, Moldaver D, Bucher O, et al. Real-world predictors of survival in patients with limited-stage small-cell lung cancer in Manitoba, Canada. Front Oncol. 2023;13:1191920.
25. Kim SY, Myung JK, Kim HR, Na I Il, Koh JS, Baek HJ, et al. Factors that predict clinical benefit of EGFR TKI therapy in patients with EGFR wild-type lung adenocarcinoma. Tuberc Respir Dis (Seoul). 2019;82(1):62–70.
26. Armocida D, Pesce A, Palmieri M, Cofano F, Palmieri G, Cassoni P, et al. EGFR-driven mutation in non-small-cell lung cancer (NSCLC) influences the features and outcome of brain metastases. J Clin Med. 2023;12(10):3372.
27. Qi H, Qiao Q, Sun X, Xing L. Survival outcomes in EGFR-mutant non-small cell lung cancer with brain metastases: Kaplan–Meier and Cox Regression analyses across treatment stages. Clinical Respiratory Journal. 2025;19(5):e70085.
28. Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R. EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients. Transl Cancer Res. 2019;8(Suppl 1):S23-47.
29. Steuer CE, Jegede OA, Dahlberg SE, Wakelee HA, Keller SM, Tester WJ, et al. Smoking behavior in patients with early-stage NSCLC: A report from ECOG-ACRIN 1505 trial. Journal of Thoracic Oncology. 2021;16(6):960–7.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 dr. Tejo Jayadi, SpPA, Dr. Charis Amarantini, M.Si, dr. Lili Ananta Saputra, SpPA, dr. Johana Puspasari Dwi Pratiwi. M.Sc, dr. Fransiska Galuh Widowati. M.Biomed
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
